IQVIA notes that digital health technologies are crucial for patient‑centric, decentralised and hybrid trials. Trial sponsors require a broad array of connected devices that integrate seamlessly and quickly; COVID‑19 has accelerated study start‑up timelines, increasing pressure on teams. Patient‑centric trials rely on familiar, easy‑to‑use devices that consolidate multiple functions and reduce the number of disparate devices, improving adherence. Remote designs open access to under‑represented populations but introduce logistical challenges such as geography and internet access. Trials must be flexible and interoperable: apps enable device configuration changes mid‑trial, and combining objective device data with subjective patient diaries offers richer insights. Regulatory considerations a

Join for free to read